Transcriptional activation of the translocated c-myc oncogene in burkitt lymphoma - PubMed (original) (raw)
Transcriptional activation of the translocated c-myc oncogene in burkitt lymphoma
J Erikson et al. Proc Natl Acad Sci U S A. 1983 Feb.
Abstract
We have previously demonstrated that translocations of V(H) genes from chromosome 14 to chromosome 8 and of the c-myc oncogene from chromosome 8 to chromosome 14 occur in Burkitt lymphomas with the t(8;14) chromosome translocation. An association of the c-myc gene with the C(mu) immunoglobulin gene has been observed in some but not all Burkitt lymphomas studied previously. In the present study, we have investigated the organization of the human heavy chain locus and of the c-myc gene in the P3HR-1 Burkitt lymphoma cell line. Becuase mouse/P3HR-1 somatic cell hybrids that retain only the 14q+ chromosome and no other human chromosome contain the human C(mu) and C(gamma) genes but not V(H) genes, we have concluded that the breakpoint on chromosome 14 in P3HR-1 cells is distal to C(mu) and between C(mu) and V(H). Thus, the breakpoint of human chromosome 14 differs in different Burkitt lymphoma cell lines. We also found that the human c-myc oncogene translocated to chromosome 14 in the P3HR-1 cell line is not recombined with the C(mu) gene. The breakpoint on human chromosome 8 may therefore also differ in different Burkitt lymphoma cell lines, because we have observed DNA rearrangement of the c-myc gene with the C(mu) gene in only some of the Burkitt lymphoma cell lines studied elsewhere. Interestingly, high levels of transcripts of the c-myc oncogene were observed in Burkitt lymphomas with translocated c-myc oncogenes both rearranged and unrearranged. Therefore, the translocation of a c-myc oncogene to the heavy chain locus on human chromosome 14 is apparently sufficient for its transcriptional activation and may be an essential step in the pathway leading to neoplasia.
Similar articles
- Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.
ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. ar-Rushdi A, et al. Science. 1983 Oct 28;222(4622):390-3. doi: 10.1126/science.6414084. Science. 1983. PMID: 6414084 - Expression of the human immunoglobulin heavy chain gene of the 14q+ chromosome in a t(8;14)-positive Burkitt lymphoma cell line demonstrated in somatic cell hybrids.
Versnel MA, van Dongen JJ, Geurts van Kessel AH, de Klein A, Bos NA, Hagemeijer A. Versnel MA, et al. Cancer Genet Cytogenet. 1986 Jan 15;19(3-4):321-30. doi: 10.1016/0165-4608(86)90061-0. Cancer Genet Cytogenet. 1986. PMID: 3080223 - Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas.
Adams JM, Gerondakis S, Webb E, Corcoran LM, Cory S. Adams JM, et al. Proc Natl Acad Sci U S A. 1983 Apr;80(7):1982-6. doi: 10.1073/pnas.80.7.1982. Proc Natl Acad Sci U S A. 1983. PMID: 6572957 Free PMC article. - New genetics of Burkitt's lymphoma and other non-Hodgkin's lymphomas.
Aisenberg AC. Aisenberg AC. Am J Med. 1984 Dec;77(6):1083-90. doi: 10.1016/0002-9343(84)90192-x. Am J Med. 1984. PMID: 6439038 Review. - The effect of translocations on the cellular myc gene in Burkitt lymphomas.
Mitchell KF, Battey J, Hollis GF, Moulding C, Taub R, Leder P. Mitchell KF, et al. J Cell Physiol Suppl. 1984;3:171-7. doi: 10.1002/jcp.1041210420. J Cell Physiol Suppl. 1984. PMID: 6378935 Review.
Cited by
- Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers.
Torne AS, Robertson ES. Torne AS, et al. Cancers (Basel). 2024 Feb 29;16(5):991. doi: 10.3390/cancers16050991. Cancers (Basel). 2024. PMID: 38473352 Free PMC article. Review. - Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Kneppers J, Bergman AM, Zwart W. Kneppers J, et al. Adv Exp Med Biol. 2022;1390:255-275. doi: 10.1007/978-3-031-11836-4_15. Adv Exp Med Biol. 2022. PMID: 36107324 Review. - Targeting complexes of super-enhancers is a promising strategy for cancer therapy.
Zheng C, Liu M, Fan H. Zheng C, et al. Oncol Lett. 2020 Sep;20(3):2557-2566. doi: 10.3892/ol.2020.11855. Epub 2020 Jul 10. Oncol Lett. 2020. PMID: 32782573 Free PMC article. Review. - Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.
Bresnick EH, Johnson KD. Bresnick EH, et al. Blood Adv. 2019 Jul 9;3(13):2045-2056. doi: 10.1182/bloodadvances.2019000378. Blood Adv. 2019. PMID: 31289032 Free PMC article. Review. - Regulation of T cell immunity by cellular metabolism.
Hu Z, Zou Q, Su B. Hu Z, et al. Front Med. 2018 Aug;12(4):463-472. doi: 10.1007/s11684-018-0668-2. Epub 2018 Aug 16. Front Med. 2018. PMID: 30112717 Review.
References
- Lancet. 1971 Oct 30;2(7731):971-2 - PubMed
- Nature. 1972 May 5;237(5349):33-4 - PubMed
- Nature. 1974 Sep 6;251(5470):77-9 - PubMed
- J Mol Biol. 1975 Nov 5;98(3):503-17 - PubMed
- Int J Cancer. 1976 Jan 15;17(1):47-56 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials